Overexpression of TIM-3 on exhausted CD4+ and CD8+ T cells and leukemic cells in CML, ALL, and CLL patients could be a prognostic risk factor for poor therapeutic response and relapse in patients. This evidence concerns the gene HAVCR2 and B-cell chronic lymphocytic leukemia.